50 related articles for article (PubMed ID: 35767454)
1. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
2. Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.
Kuo KHM; Grace RF; van Beers EJ; Barcellini W; Glenthøj A; Holzhauer S; Beynon V; Morris S; Li J; Zagadailov E; Patel P; Al-Samkari H
Am J Hematol; 2024 Jul; 99(7):1415-1419. PubMed ID: 38712615
[TBL] [Abstract][Full Text] [Related]
3. Updates and advances in pyruvate kinase deficiency.
Luke N; Hillier K; Al-Samkari H; Grace RF
Trends Mol Med; 2023 May; 29(5):406-418. PubMed ID: 36935283
[TBL] [Abstract][Full Text] [Related]
4. Anemia in the Neonate: The Differential Diagnosis and Treatment.
Nassin ML; Lapping-Carr G; de Jong JL
Pediatr Ann; 2015 Jul; 44(7):e159-63. PubMed ID: 26171704
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.
Parekh DS; Eaton WA; Thein SL
Blood; 2024 Mar; 143(10):866-871. PubMed ID: 38118071
[TBL] [Abstract][Full Text] [Related]
6. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of pyruvate kinase deficiency: A systematic literature review.
Secrest MH; Storm M; Carrington C; Casso D; Gilroy K; Pladson L; Boscoe AN
Eur J Haematol; 2020 Aug; 105(2):173-184. PubMed ID: 32279356
[TBL] [Abstract][Full Text] [Related]
8. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
9. Acquired pseudoxanthoma elasticum-like syndrome and pyruvate kinase deficiency: a case of iron overload?
Robert M; Audebert S; Eveillard JR; Galacteros F; El Aridi L; Glen LF; Billon C; Misery L; Abasq-Thomas C
Eur J Dermatol; 2023 Jun; 33(3):319-320. PubMed ID: 37594352
[No Abstract] [Full Text] [Related]
10. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Grace RF
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
[TBL] [Abstract][Full Text] [Related]
11. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
12. Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.
De SK
Curr Med Chem; 2024; 31(6):683-687. PubMed ID: 37125655
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat-Associated Rib Fracture in a Hemolytic Anemia Patient.
Abouelkheer Y; Ladel L; Boxer D; Shafique S
Cureus; 2024 Mar; 16(3):e55658. PubMed ID: 38586665
[TBL] [Abstract][Full Text] [Related]
14. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. Reply.
Al-Samkari H; Beynon V; van Beers EJ
N Engl J Med; 2022 Jun; 386(26):2539. PubMed ID: 35767454
[No Abstract] [Full Text] [Related]
15. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Shah AJ; Schwartz JD; Segovia JC
N Engl J Med; 2022 Jun; 386(26):2538-2539. PubMed ID: 35767453
[No Abstract] [Full Text] [Related]
16. Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.
Al-Samkari H; Grace RF; Glenthøj A; Andres O; Barcellini W; Galacteros F; Kuo KHM; Layton DM; Morado M; Viprakasit V; Tai F; Urbstonaitis R; Morales J; McGee B; Beers EJV
Haematologica; 2024 Mar; 109(3):963-967. PubMed ID: 37731369
[No Abstract] [Full Text] [Related]
17. Mitapivat for treatment of pyruvate kinase deficiency.
Costa FF
Lancet Haematol; 2022 Oct; 9(10):e708-e709. PubMed ID: 35988547
[No Abstract] [Full Text] [Related]
18. Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD.
Schwartz JD; Barcellini W; Grace RF; Bianchi P; Zanella A; López Lorenzo JL; Sevilla J; Shah AJ; Glader B; Nicoletti E; Navarro Ordoñez S; Segovia JC
Am J Hematol; 2022 Mar; 97(3):E120-E125. PubMed ID: 34989415
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
